Anecortave | CAS#10184-70-0 | Angiogenesis Inhibitor

MedKoo Cat#: 592408 | Name: Anecortave

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Anecortave is an Angiogenesis Inhibitor. Anecortave acetate possesses a mechanism of action that decreases CNV growth irrespective of the inciting angiogenic stimulus, has a dosing-interval that allows its use as prophylactic therapy, and is safe.

Chemical Structure

Anecortave

CAS#10184-70-0

Theoretical Analysis

MedKoo Cat#: 592408

Name: Anecortave

CAS#: 10184-70-0

Chemical Formula:

Exact Mass: 0.0000

Molecular Weight: 0.00

Elemental Analysis:

Price and Availability

Size	Price	Availability	Quantity

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

7753-60-8 (acetate) 10184-70-0

Synonym

Anecortave; AL 4940; AL-4940; AL4940

IUPAC/Chemical Name

Anecortave

InChi Key

BCFCRXOJOFDUMZ-ONKRVSLGSA-N

InChi Code

InChI=1S/C21H28O4/c1-19-8-5-14(23)11-13(19)3-4-15-16(19)6-9-20(2)17(15)7-10-21(20,25)18(24)12-22/h6,11,15,17,22,25H,3-5,7-10,12H2,1-2H3/t15-,17+,19+,20+,21+/m1/s1

SMILES Code

C[C@]12CCC(C=C1CC[C@@H]3C2=CC[C@@]4(C)[C@H]3CC[C@]4(O)C(CO)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 0.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Leung E, Landa G. Update on current and future novel therapies for dry age-related macular degeneration. Expert Rev Clin Pharmacol. 2013 Sep;6(5):565-79. doi: 10.1586/17512433.2013.829645. Epub 2013 Aug 24. Review. PubMed PMID: 23971874. 2: Reeves EKM, Hoffman EP, Nagaraju K, Damsker JM, McCall JM. VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Bioorg Med Chem. 2013 Apr 15;21(8):2241-2249. doi: 10.1016/j.bmc.2013.02.009. Epub 2013 Feb 18. Erratum in: Bioorg Med Chem. 2015 Apr 1;23(7):1664. PubMed PMID: 23498916; PubMed Central PMCID: PMC4088988. 3: Geltzer A, Turalba A, Vedula SS. Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD005022. doi: 10.1002/14651858.CD005022.pub3. Review. PubMed PMID: 23440797; PubMed Central PMCID: PMC4269233. 4: Kumar S, Shah S, Deutsch ER, Tang HM, Danias J. Triamcinolone acetonide decreases outflow facility in C57BL/6 mouse eyes. Invest Ophthalmol Vis Sci. 2013 Feb 1;54(2):1280-7. doi: 10.1167/iovs.12-11223. PubMed PMID: 23322580; PubMed Central PMCID: PMC3576053. 5: Shepard AR, Conrow RE, Pang IH, Jacobson N, Rezwan M, Rutschmann K, Auerbach D, Sriramaratnam R, Cornish VW. Identification of PDE6D as a molecular target of anecortave acetate via a methotrexate-anchored yeast three-hybrid screen. ACS Chem Biol. 2013 Mar 15;8(3):549-58. doi: 10.1021/cb300296m. Epub 2013 Jan 9. PubMed PMID: 23301619. 6: Stalmans I, Callanan DG, Dirks MS, Moster MR, Robin AL, Van Calster J, Scheib SA, Dickerson JE Jr, Landry TA, Bergamini MV. Treatment of steroid-induced elevated intraocular pressure with anecortave acetate: a randomized clinical trial. J Ocul Pharmacol Ther. 2012 Dec;28(6):559-65. doi: 10.1089/jop.2012.0063. Epub 2012 Aug 3. PubMed PMID: 22860637; PubMed Central PMCID: PMC3505827. 7: Razeghinejad MR, Katz LJ. Steroid-induced iatrogenic glaucoma. Ophthalmic Res. 2012;47(2):66-80. doi: 10.1159/000328630. Epub 2011 Jul 13. Review. PubMed PMID: 21757964. 8: Houston SK, Piña Y, Murray TG, Boutrid H, Cebulla C, Schefler AC, Shi W, Celdran M, Feuer W, Merchan J, Lampidis TJ. Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors. Clin Ophthalmol. 2011 Jan 27;5:129-37. doi: 10.2147/OPTH.S15179. PubMed PMID: 21339806; PubMed Central PMCID: PMC3037041. 9: Hodge W, Brown A, Kymes S, Cruess A, Blackhouse G, Hopkins R, McGahan L, Sharma S, Pan I, Blair J, Vollman D, Morrison A. Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation. Can J Ophthalmol. 2010 Jun;45(3):223-30. doi: 10.3129/i10-047. Review. PubMed PMID: 20628420. 10: Missel P, Chastain J, Mitra A, Kompella U, Kansara V, Duvvuri S, Amrite A, Cheruvu N. In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment. J Ocul Pharmacol Ther. 2010 Apr;26(2):137-46. doi: 10.1089/jop.2009.0132. PubMed PMID: 20415622; PubMed Central PMCID: PMC3158576. 11: Kaufman PL. Suppression and reduction of corticosteroid-induced ocular hypertension by anecortave in sheep. Arch Ophthalmol. 2010 Mar;128(3):365-6. doi: 10.1001/archophthalmol.2009.410. PubMed PMID: 20212210. 12: Candia OA, Gerometta R, Millar JC, Podos SM. Suppression of corticosteroid-induced ocular hypertension in sheep by anecortave. Arch Ophthalmol. 2010 Mar;128(3):338-43. doi: 10.1001/archophthalmol.2009.387. PubMed PMID: 20212205. 13: Bajenaru ML, Piña Y, Murray TG, Cebulla CM, Feuer W, Jockovich ME, Marin Castaño ME. Gelatinase expression in retinoblastoma: modulation of LH(BETA)T(AG) retinal tumor development by anecortave acetate. Invest Ophthalmol Vis Sci. 2010 Jun;51(6):2860-4. doi: 10.1167/iovs.09-4500. Epub 2010 Jan 27. PubMed PMID: 20107171; PubMed Central PMCID: PMC2891454. 14: Prata TS, Tavares IM, Mello PA, Tamura C, Lima VC, Belfort R. Hypotensive effect of juxtascleral administration of anecortave acetate in different types of glaucoma. J Glaucoma. 2010 Sep;19(7):488-92. doi: 10.1097/IJG.0b013e3181c4b0e8. PubMed PMID: 20051887. 15: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Oct;31(8):541-57. PubMed PMID: 19967103. 16: Unoki N, Murakami T, Ogino K, Nukada M, Yoshimura N. Time-lapse imaging of retinal angiogenesis reveals decreased development and progression of neovascular sprouting by anecortave desacetate. Invest Ophthalmol Vis Sci. 2010 May;51(5):2347-55. doi: 10.1167/iovs.09-4158. Epub 2009 Dec 3. PubMed PMID: 19959648. 17: Shah AR, Del Priore LV. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration. Ophthalmology. 2009 Oct;116(10):1901-7. doi: 10.1016/j.ophtha.2009.03.055. Epub 2009 Jul 9. PubMed PMID: 19592101. 18: Boutrid H, Piña Y, Cebulla CM, Feuer WJ, Lampidis TJ, Jockovich ME, Murray TG. Increased hypoxia following vessel targeting in a murine model of retinoblastoma. Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5537-43. doi: 10.1167/iovs.09-3702. Epub 2009 Jul 2. PubMed PMID: 19578014. 19: Robin AL, Suan EP, Sjaarda RN, Callanan DG, Defaller J; Alcon Anecortave Acetate for IOP Research Team. Reduction of intraocular pressure with anecortave acetate in eyes with ocular steroid injection-related glaucoma. Arch Ophthalmol. 2009 Feb;127(2):173-8. doi: 10.1001/archophthalmol.2008.595. PubMed PMID: 19204235. 20: Li X, Wang YS. [Present status of studies on the treatment of choroidal neovascularization by Anecortave acetate]. Zhonghua Yan Ke Za Zhi. 2008 Jun;44(6):571-4. Review. Chinese. PubMed PMID: 19035252.